Paclitaxel/epirubcin/carboplatin

PreclinicalSmall molecule

Paclitaxel/epirubcin/carboplatin is one of 20 small molecule programs targeting Endometrial Carcinoma. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Endometrial CarcinomaActive, not recruiting

Endometrial CarcinomaPreclinical

Active, not recruiting

Competition

Competitive Landscape

21 competitors in Endometrial Carcinoma

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Approved

1 2

Taxol

Teva

Phase 3

6 3

Keytruda

Merck & Co.

Phase 3

4 4

IC-Green

Megace

3 6

Depo-Provera

Eli Lilly

Phase 3

1 7

Afinitor

Novartis

Phase 2

1 8

Kisqali

Novartis

Phase 2

1 9

Trodelvy

Gilead

Phase 2

1 10

Femara

Novartis

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Endometrial Carcinoma1 trial

Combination Chemotherapy of Paclitaxel and Carboplatin With or Without Anthracycline as Aneo Adjuvant Treatment in Advanced Endometrial Carcinoma

Not yet recruiting·SSohag University·N/A·NCT06102252·80 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Paclitaxel/epirubcin/carboplatin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Paclitaxel/epirubcin/carboplatin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Paclitaxel/epirubcin/carboplatin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sohag University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SSohag University

Paclitaxel/epirubcin/carboplatin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Endometrial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News